Table 2

Incidence of adverse events by frequency (reported by more than one subject)

Treatment group
Placebo (n = 5)Mavrilimumab* (n = 27)
Adverse eventNo of AEsNo (%) of subjectsNo of AEsNo (%) of subjects
Total134 (80)6920 (74)
Nasopharyngitis32 (40)1110 (37)
Headache22 (40)75 (19)
Diarrhoea11 (20)55 (19)
Back pain11 (20)44 (15)
Peripheral oedema0033 (11)
Nausea11 (20)22 (7)
Bronchitis0022 (7)
Dizziness0022 (7)
Hypertension0022 (7)
Pharyngolaryngeal pain0022 (7)
Vomiting11 (20)11 (4)
  • * All doses. AEs were classified according to the terminology of the Medical Dictionary for Regulatory Activities (version 11).

  • AE, adverse event.